Improvement of all JIA-ACR core components at the end of part 2 (week 40) for the ITT population receiving tocilizumab in parts 1 and 2 (n=82)* compared with baseline
| JIA-ACR core response variables† | Baseline | Week 40 | Week 40 (change from baseline)‡ |
|---|---|---|---|
| Joints with active arthritis (range, 0–71) | 19.7 (13.95) | 3.2 (8.06) | −14.5 (11.14) |
| Joints with a limitation of movement (range, 0–67) | 16.5 (13.81) | 3.9 (6.95) | −10.2 (8.97) |
| Assessment of patient overall well-being, VAS (range, 0–100) | 45.5 (23.11) | 8.8 (16.12) | −31.1 (28.52) |
| Physician global assessment of disease activity, VAS (range, 0–100) | 57.8 (20.30) | 6.2 (7.75) | −45.6 (21.47) |
| CHAQ-DI (range, 0–3) | 1.216 (0.67) | 0.333 (0.47) | −0.804 (0.65) |
| ESR (mm/h) | 31.7 (22.88) | 5.4 (6.08) | −25.2 (21.97) |
*Ad hoc analysis.
†Values are mean (SD).
‡Change from baseline was calculated using last-observation-carried-forward imputation for missing values; in other columns, missing values were not imputed.
CHAQ-DI, Childhood Health Assessment Questionnaire-Disability Index; ESR, erythrocyte sedimentation rate; ITT, intent-to-treat; JIA-ACR, juvenile idiopathic arthritis-American College of Rheumatology; ULN, upper limit of normal; VAS, visual analogue scale (0–100 mm).